1. Epidemiology & Biology
- Most common solid tumor in males aged 15–35 years
- Highly curable, even in advanced stages, due to platinum sensitivity
- Histologic subtypes:
Tumor Markers:
Staging (TNM + Serum Markers):
- Stage I: Confined to testis
- Stage II: Retroperitoneal lymph node involvement
- Stage III: Distant metastases (e.g., lungs, liver, brain)
Staging determines risk group (good, intermediate, poor) per IGCCCG criteria.
Treatment Overview:
1. Stage I:
- Orchiectomy is curative for many patients
- Active surveillance vs. adjuvant chemotherapy (e.g., 1 cycle BEP) or radiation (seminoma only)
- Chemotherapy is cornerstone
2. Treatment Principles
- Cisplatin-based chemotherapy is the cornerstone in systemic treatment
- Surgery (orchiectomy) is initial step in all stages → followed by surveillance, adjuvant chemo, or radiation depending on histology & stage
First-Line Chemotherapy Regimens
(All use cisplatin — carboplatin substitution is not recommended for curative intent)
Good-risk (IGCCCG criteria)
Intermediate/Poor-risk
- BEP × 4 cycles (same as above, extended to 4 cycles)
- VIP × 4 cycles (Etoposide + Ifosfamide + Cisplatin) — alternative if bleomycin contraindicated
| Agent | Toxicities | Monitoring / Notes |
|---|---|---|
| Bleomycin | Pulmonary toxicity | Baseline PFTs; cumulative dose limit (~400 units) |
| Etoposide | Myelosuppression, alopecia | CBC, avoid in severe renal/hepatic impairment |
| Cisplatin | Nephrotoxicity, ototoxicity, neuropathy, N/V | Hydration, electrolytes (Mg/K), antiemetics |
| Growth Factors | Febrile neutropenia prophylaxis (risk-based) | May be needed in poor-risk disease |
3. Cisplatin’s Role & Rationale
- Platinum sensitivity of GCTs is among the highest of all cancers
- Cisplatin has curative potential even in metastatic disease
- Carboplatin is inferior in relapse-free survival and should not replace cisplatin in first-line GCT therapy unless absolutely contraindicated
4. Toxicity & Monitoring in Testicular Cancer Regimens
BEP-specific pharmacist notes
| Agent | Major Toxicities | Pharmacist Monitoring & Prevention |
|---|---|---|
| Bleomycin | Pulmonary fibrosis (cumulative >400 U), hypersensitivity, skin changes | Baseline PFTs, avoid high O₂ during anesthesia, monitor for cough/dyspnea |
| Etoposide | Myelosuppression, hypotension (fast infusion), secondary AML (rare) | CBC, control infusion rate (≥30–60 min), BP monitoring |
| Cisplatin | Nephrotoxicity, ototoxicity, electrolyte wasting, severe N/V, neuropathy | Aggressive hydration, triple antiemetics, monitor renal function, Mg²⁺/K⁺/Ca²⁺, audiometry |
Supportive Care Musts
- Hydration: Pre/post cisplatin with NS ± mannitol
- Antiemetics: NK1 + 5-HT3 + dexamethasone
- Pulmonary monitoring: Bleomycin risk — avoid G-CSF during bleomycin-containing regimens unless necessary, as it may ↑ pulmonary toxicity
- Fertility preservation: Offer sperm banking before chemotherapy (cisplatin can cause infertility)
5. Key Pharmacist Pearls
- Always use cisplatin in curative regimens — carboplatin is only for seminoma stage I adjuvant setting in select patients
- Avoid unnecessary dose reductions — optimal dosing is critical for cure
- Monitor cumulative bleomycin dose and counsel patients on early pulmonary toxicity symptoms
- Counsel on ototoxicity and neuropathy — these can be permanent
- Educate on fertility, fatigue, alopecia, mucositis, and supportive medication use
- Long-term survivorship: monitor for metabolic syndrome, cardiovascular disease, and secondary malignancies
Survivorship Issues:
- Long-term monitoring for:
Relapsed/Refractory Disease
- Salvage regimens: VeIP (Vinblastine + Ifosfamide + Cisplatin), TIP (Paclitaxel + Ifosfamide + Cisplatin), or high-dose chemo with stem cell support